Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.

Evan B CunninghamBehzad HajarizadehOlav DalgardJanaki AminMargaret HellardGraham R FosterPhilip BruggmannBrian ConwayMarkus BackmundGeert RobaeysTracy SwanPhilippa S MarksSophie QuieneTanya L ApplegateMartin WeltmanDavid ShawAdrian DunlopJulie BruneauHåvard MidgardStefan BourgeoisMaria Christine ThurnheerGregory J DoreJason Grebelynull null

Published in: BMC infectious diseases (2017)

This study demonstrated a high adherence to directly observed PEG-IFN and self-administered ribavirin among people with ongoing injecting drug use or receiving OST. These data also suggest that shortening therapy from 24 to 12 weeks can lead to improved treatment completion. Treatment completion was associated with improved response to therapy. ACTIVATE trial registration number: NCT01364090 - May 31, 2011.

Keyphrases

hepatitis c virus
dendritic cells
immune response
clinical trial
randomized controlled trial
study protocol
mesenchymal stem cells
metabolic syndrome
phase ii
hiv infected
glycemic control
open label
gestational age